Optimizing Patient Care in EGFR-Mutated NSCLC: AE Management and Supportive Care Strategies

Panelists discuss how adverse event profiles, management strategies, and patient education approaches differ among EGFR-targeted therapies for non–small cell lung cancer, including oral tyrosine kinase inhibitors like osimertinib and infusion therapies like amivantamab, with emphasis on monitoring requirements and treatment sequencing decisions.

Panelists discuss how venous thromboembolism risk assessment and prophylaxis decisions in patients with non–small cell lung cancer require careful consideration of individual risk factors, patient education strategies, and balanced communication about the benefits and concerns of preventive measures, particularly in the context of amivantamab therapy.